4D Path
4D Path is dedicated to personalizing cancer care through advanced tumor response prediction technology. Their innovative QPOR™ platform directly measures and quantifies cell cycle deregulations and tumor microenvironment dynamics from routine biopsy images, enabling precise prediction of patient response to therapy. With a mission to democratize precision diagnostics, 4D Path aims to deliver faster, more accurate, and personalized cancer treatment solutions, improving patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Digital image-to-report tumor profiling platform (patented treatment-prediction platform)
A cloud-based, end-to-end platform that analyzes digitized H&E whole-slide and cytology images to generate diagnostic outputs, quantitative biomarker indices, and treatment-response predictions without requiring additional molecular tests.
Digital image-to-report tumor profiling platform (patented treatment-prediction platform)
A cloud-based, end-to-end platform that analyzes digitized H&E whole-slide and cytology images to generate diagnostic outputs, quantitative biomarker indices, and treatment-response predictions without requiring additional molecular tests.
Services
Designs and executes clinical validation studies and collaborates with academic and clinical partners to validate predictive biomarkers and platform performance in real-world and trial settings.
Embeds image-analysis services into existing pathology viewers and PACS, provides format conversion, and supports scanner-agnostic deployment to fit established lab workflows.
Develops customized predictive signatures for specific therapies to support translational research and pharmaceutical development.
Provides automated image-based qualification of H&E staining protocols and quantitative adequacy metrics for laboratory quality control.
Supports regulatory strategy and preparation for submissions of image-derived diagnostic adjuncts, informed by prior experience with Breakthrough Device designation.
Designs and executes clinical validation studies and collaborates with academic and clinical partners to validate predictive biomarkers and platform performance in real-world and trial settings.
Embeds image-analysis services into existing pathology viewers and PACS, provides format conversion, and supports scanner-agnostic deployment to fit established lab workflows.
Develops customized predictive signatures for specific therapies to support translational research and pharmaceutical development.
Provides automated image-based qualification of H&E staining protocols and quantitative adequacy metrics for laboratory quality control.
Supports regulatory strategy and preparation for submissions of image-derived diagnostic adjuncts, informed by prior experience with Breakthrough Device designation.
Expertise Areas
- Histopathology image analysis
- Computational biomarker development
- Digital pathology workflow integration
- Translational clinical validation
Key Technologies
- Whole-slide image (WSI) analysis
- Physics-informed computational modeling
- Quantitative image biomarker generation
- Cloud-native scalable compute
News & Updates
4D Path Prepping FDA Submission for AI-Enabled Breast Cancer Digital Pathology Product
4D Path is preparing to submit its AI-enabled breast cancer digital pathology product to the FDA, with the first product, the 4D Q-plasia OncoReader Breast, having received Breakthrough Device Designation.
4D Path Adds New Processing Capabilities to Algorithm for Accelerated Cancer Diagnosis
The company has extended its platform to analyze various image formats and cytology images, enabling faster and more comprehensive cancer diagnostics.
4D Path President, CTO, and Co-Founder Tathagata Dasgupta featured in Healthcare IT Today
Insights from 4D Path leadership on digital health technology and personalized cancer diagnosis.
Advances in Digital Pathology
An article by 4D Path’s founder about automating image-based detection and prognostic evaluation of breast cancers.
4D Path Expands Scientific Advisory Board with Global Leaders in Oncology and Pathology
The company has assembled a distinguished SAB to accelerate clinical translation of its platform.
4D Path Secures First Action Allowance Patent to Process Digital Whole Slide Images
The USPTO has approved a patent application for 4D Path’s method of processing digital pathology images, enhancing diagnostic accuracy.
4D Path Prepping FDA Submission for AI-Enabled Breast Cancer Digital Pathology Product
4D Path is preparing to submit its AI-enabled breast cancer digital pathology product to the FDA, with the first product, the 4D Q-plasia OncoReader Breast, having received Breakthrough Device Designation.
4D Path Adds New Processing Capabilities to Algorithm for Accelerated Cancer Diagnosis
The company has extended its platform to analyze various image formats and cytology images, enabling faster and more comprehensive cancer diagnostics.
4D Path President, CTO, and Co-Founder Tathagata Dasgupta featured in Healthcare IT Today
Insights from 4D Path leadership on digital health technology and personalized cancer diagnosis.
Advances in Digital Pathology
An article by 4D Path’s founder about automating image-based detection and prognostic evaluation of breast cancers.
4D Path Expands Scientific Advisory Board with Global Leaders in Oncology and Pathology
The company has assembled a distinguished SAB to accelerate clinical translation of its platform.
4D Path Secures First Action Allowance Patent to Process Digital Whole Slide Images
The USPTO has approved a patent application for 4D Path’s method of processing digital pathology images, enhancing diagnostic accuracy.